文献速递膀胱癌与上尿路尿路上皮癌

首次经尿道膀胱肿瘤电切术时估算肾小球滤过率降低(eGFR <60 mL/min/1.73 m²)是后续复发和进展的重要预测因素

Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
PubMed 文献 · BJU Int · 2017-06-23

多中心数据库纳入首次经尿道膀胱肿瘤电切术(TURBT)前有血清肌酐值的非肌层浸润性膀胱癌(NMIBC)患者,评估估算肾小球滤过率(eGFR)<60 mL/min/1.73 m²与复发或进展的关系。中位随访3.7年,多变量分析显示eGFR <60 mL/min/1.73 m²是肿瘤复发的预测因素(HR 1.5,95%CI 1.2-1.9,P=0.002),且与进展为肌层浸润性疾病相关(HR 3.7,95%CI 1.75-7.94,P=0.001)。结论认为首次TURBT时中度慢性肾脏病与无复发生存期和无进展生存期降低相关,肾功能降低的患者应考虑加强监测。

要点

  • eGFR <60 mL/min/1.73 m²是NMIBC复发的预测因素(HR 1.5,95%CI 1.2-1.9,P=0.002)。
  • eGFR <60 mL/min/1.73 m²与进展为肌层浸润性疾病相关(HR 3.7,95%CI 1.75-7.94,P=0.001)。
  • 5年无复发生存率eGFR ≥60组为46%,eGFR <60组为27%(P < 0.001)。

核心结论

  • 首次TURBT时中度慢性肾脏病与无复发生存期和无进展生存期降低相关。
  • 肾功能降低的患者应考虑加强监测。

研究设计与样本

  • 多中心数据库识别首次TURBT前有血清肌酐值的患者。
  • 采用CKD-流行病学协作公式计算患者eGFR。
  • 共识别727例患者,中位(四分位距)年龄69.8(60.1-77.6)岁。
  • 632例患者有eGFR数据。
  • 采用Cox比例风险模型评估与无复发生存期和无进展生存期的关联。

主要发现

  • 中位(四分位距)随访3.7(1.5-6.5)年期间,400例(55%)患者复发,145例(19.9%)患者肿瘤分期或分级进展。
  • 根据eGFR,183例患者被确定为中度或重度慢性肾脏病。
  • 多变量分析确定eGFR <60 mL/min/1.73 m²(HR 1.5,95%CI 1.2-1.9,P=0.002)为肿瘤复发的预测因素。
  • 5年无复发生存率eGFR ≥60 mL/min/1.73 m²组为46%,eGFR <60 mL/min/1.73 m²组为27%(P < 0.001)。
  • 多变量分析显示eGFR <60 mL/min/1.73 m²(HR 3.7,95%CI 1.75-7.94,P=0.001)与进展为肌层浸润性疾病相关。

临床怎么用

  • 作者认为,首次TURBT时中度慢性肾脏病与无复发生存期和无进展生存期降低相关。
  • 作者建议,肾功能降低的患者应考虑加强监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate if moderate chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 ] is associated with high rates of non-muscle-invasive bladder cancer (NMIBC) recurrence or progression. PATIENTS AND METHODS: A multi-institutional database identified patients with serum creatinine values prior to first transurethral resection of bladder tumour (TURBT). The CKD-epidemiology collaboration formula calculated patient eGFR. Cox proportional hazards models evaluated associations with recurrence-free (RFS) and progression-free survival (PFS). RESULTS: In all, 727 patients were identified with a median (interquartile range [IQR]) patient age of 69.8 (60.1-77.6) years. Data for eGFR were available for 632 patients. During a median (IQR) follow-up of 3.7 (1.5-6.5) years, 400 (55%) patients had recurrence and 145 (19.9%) patients had progression of tumour stage or grade. Moderate or severe CKD was identified in 183 patients according to eGFR. Multivariable analysis identified an eGFR of <60 mL/min/1.73 m2 (hazard ratio [HR] 1.5, 95% confidence interval [CI]: 1.2-1.9; P = 0.002) as a predictor of tumour recurrence. The 5-year RFS rate was 46% for patients with an eGFR of ≥60 mL/min/1.73 m2 and 27% for patients with an eGFR of <60 mL/min/1.73 m2 (P < 0.001). Multivariable analysis showed that an eGFR of <60 mL/min/1.73 m2 (HR 3.7, 95% CI: 1.75-7.94; P = 0.001) was associated with progression to muscle-invasive disease. The 5-year PFS rate was 83% for patients with an eGFR of ≥60 mL/min/1.73 m2 and 71% for patients with an eGFR of <60 mL/min/1.73 m2 (P = 0.01). CONCLUSION: Moderate CKD at first TURBT is associated with reduced RFS and PFS. Patients with reduced renal function should be considered for increased surveillance.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Blute ML, Kucherov V, Rushmer TJ, et al. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017. PMID: 28464520. doi:10.1111/bju.13904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。